NEW YORK (GenomeWeb News) – Decode Genetics reported after the close of the market on Tuesday that its fourth-quarter 2008 revenues increased 21 percent and its net loss dropped sharply. But the firm only has enough liquid assets to fund operations into the second quarter of this year, and said that it is seeking additional funds through a variety of options.

The Reykjavik, Iceland-based genetic test and drug developer brought in revenues of $16.1 million for the three-month period ended Dec. 31, 2008, compared to revenues of $13.3 million for the fourth quarter of 2007.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.